RG 101

Drug Profile

RG 101

Alternative Names: RG-101; RG-101Rx

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Stanford University
  • Developer Regulus Therapeutics
  • Class Antisense oligonucleotides; Antivirals; MicroRNAs
  • Mechanism of Action MIRN122 microRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 27 Jul 2016 Regulus Therapeutics receives written communication from the US FDA related to the clinical hold of RG 101 in Hepatitis C virus
  • 27 Jun 2016 Regulus Therapeutics completes enrolment in phase I clinical trials in Hepatitis C in USA
  • 27 Jun 2016 Regulus Therapeutics receives a verbal notice from the US FDA that its IND application for RG 101 has been placed on clinical hold in Hepatitis C virus (HCV) infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top